Notably, several drug-gene pairs—including those targeting CASP8, CASP10, KCNQ1, and HSPA8—are not currently approved nor under clinical evaluation for LN, representing investigational candidates with potential for future development in hematologic malignancies. Here, KCNQ1 is linked to hematologic disorder.